Pharmaxis Ltd (AU:SNT) has released an update.
Syntara Limited is halfway through recruiting for its Phase 2 clinical trial of SNT-5505 for myelofibrosis, with completion expected in the first half of 2024 and interim results due in December 2024. The trial, conducted globally, could be a game-changer in a market worth over $1 billion annually. Positive trial outcomes may allow Syntara to discuss pivotal study designs with the FDA and seek commercialization partners.
For further insights into AU:SNT stock, check out TipRanks’ Stock Analysis page.
